Zepatier - PBAC yes for GT1 but no for GT3

This topic has 2 replies, 3 voices, and was last updated 8 years, 2 months ago by Paul-Jarman-facebook.

Viewing 3 posts - 1 through 3 (of 3 total)

Author

Posts
23 August 2016 at 10:50 am #22471
Dr James
- Topics: 264
- Replies: 1,968
- Total: 2,232
- Guardian Angel
@fixhepc
The Pharmaceutical Benefits Advisory Committee (PBAC) has agreed there is a need for interferon-free treatment regimens for people with hepatitis C – genotypes 4 and 6. At its July meeting PBAC recommended that the combination of grazoprevir + elbasvir (Zepatier®) be listed on the Pharmaceutical Benefits Scheme (PBS). It was also recommended as a further option for people with genotype 1. Merck Sharpe and Dohme, who produce the medicine, also sought PBS listing for genotype 3 but PBAC considered there was insufficient data to support use with genotype 3 at this time. [which is a damn pity because Canada disagrees]

YMMV
23 August 2016 at 12:26 pm #22475
pat1
- Topics: 5
- Replies: 334
- Total: 339
- Guardian Angel
@pat1
That is wonderful news for genotypes 4 and 6 including G1’s but it seems so very unfair for those with G3. Where is the dislike tab?

gt 1a VL 6m
F2/3 FibroScan – 9KPa in 2011 and 7KPa in 2015
sof/dac 10 December for 12 weeks
pre tx alt 85 ast 51
4 wk alt 34 ast 31 UND <35
8 wk alt 29 ast 32 UND <15
12wk alt 25 ast 25 EOT 3.3.16
SVR24 UND KPa5.3 F0 in normal range
I am well
.forever grateful to fixhepc
3 September 2016 at 11:31 am #22775
Paul-Jarman-facebook
- Topics: 8
- Replies: 373
- Total: 381
- Guardian Angel
@paul-jarman-facebook
Maybe it’s possible that Zepatier could interfere with the PBAC’s deal with Gilead and funding caps given that G3 is more prevelant here.

Two time relapser.

SVR 4 achieved 12/16 at last
SVR 12 achieved 22/02/2017 The Bastard has been defeated

GT 3 – about 28 yrs with HCV
Author

Posts

Viewing 3 posts - 1 through 3 (of 3 total)

You must be logged in to reply to this topic.